SUVEN LIFE SCIENCES TO SHOWCASE PHASE-3 NARCOLEPSY PROGRAM AT SLEEP 2026 🌍

• 📊 To present 3 scientific posters on Samelisant (SUVN-G3031) at the SLEEP 2026 Annual Meeting in the USA • 🚀 Presentations include the global Phase-3 AWAKE Narcolepsy Study and Phase-2 efficacy results • 😴 Samelisant targets Excessive Daytime Sleepiness (EDS) and cataplexy in narcolepsy patients • 🔬 Posters will highlight Phase-2 outcomes, study design and Phase-3 development strategy • 🤝 Management to meet investigators, KOLs and potential partners during the event • 🌎 SLEEP 2026 is a premier global sleep medicine conference with over 5,000 attendees 🟢 Impact: Positive (Strengthens visibility of Suven's lead CNS asset and could support future partnering and commercialization opportunities)

SUVEN LIFE SCIENCES LTD

← Back to feed